Cagrilintide+Semaglutide is a research blend pairing a long-acting amylin analog (Cagrilintide) with a GLP-1 receptor agonist (Semaglutide). Studied under the research designation CagriSema, the combination engages two distinct metabolic signaling systems, the amylin/calcitonin receptors and the GLP-1 receptor, allowing researchers to examine parallel and potentially complementary pathway activity. Puritide Research supplies this blend as a high-purity, research-use-only material, synthesized for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›Cagrilintide+Semaglutide 5+5 mg Vial
Product Specifications
- Application
- Combined amylin + incretin signaling research (amylin analog / GLP-1 agonist)
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- Cagrilintide: C194H312N54O59S2; Semaglutide: C187H291N45O59
- CAS Number
- Cagrilintide: 1415456-99-3; Semaglutide: 910463-68-2
- Molecular Weight
- Cagrilintide: ~4409.01 g/mol; Semaglutide: ~4113.64 g/mol
- Synonyms
- CagriSema, Cagrilintide/Semaglutide blend, amylin analog + GLP-1 agonist stack, AM833 + semaglutide
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is Cagrilintide+Semaglutide?
Cagrilintide+Semaglutide is a co-formulated blend of two research peptides. Cagrilintide is a long-acting, acylated amylin analog that engages the amylin and calcitonin receptor systems. Semaglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist.
The two components are studied together, under the research designation CagriSema, because amylinergic and incretin signaling operate through separate receptor systems that both influence metabolic pathways. In experimental models this pairing is used to investigate how the two systems behave when engaged in parallel, and how combined signaling compares with either pathway alone.
Present understanding derives from in vitro assays, animal models, and clinical research. Findings should be interpreted within their experimental context and not treated as established clinical outcomes. Puritide Research supplies this blend strictly for laboratory use; it is not approved for human or veterinary application.
Puritide Research supplies Cagrilintide+Semaglutide strictly for laboratory research use. Not for human or veterinary use.
Research Use Only
